Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Income from Non-Controlling Interests (2016 - 2017)

Spero Therapeutics (SPRO) has disclosed Income from Non-Controlling Interests for 2 consecutive years, with -$6000.0 as the latest value for Q4 2017.

  • For the quarter ending Q4 2017, Income from Non-Controlling Interests rose 99.39% year-over-year to -$6000.0, compared with a TTM value of -$1.1 million through Dec 2017, changed N/A, and an annual FY2017 reading of -$1.1 million, up 84.01% over the prior year.
  • Income from Non-Controlling Interests was -$6000.0 for Q4 2017 at Spero Therapeutics, up from -$8000.0 in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at -$6000.0 in Q4 2017 and bottomed at -$986000.0 in Q4 2016.